JPMorgan raised the firm’s price target on Argenx to EUR 580 from EUR 560 and keeps an Overweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARGX:
- argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
- argenx to Present at Upcoming Investor Conferences
- Argenx reports Q3 EPS ($1.25), consensus ($1.53)
- argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
- ARGX Earnings this Week: How Will it Perform?